A Agilent Technologies Inc.

Agilent Technologies Unveils New Analytical and Purification Solutions at HPLC 2017

Agilent Technologies Inc. (NYSE:A) today announced the introduction of several new products to complete the InfinityLab LC series, part of the InfinityLab family of instruments, columns, and supplies that work seamlessly together, alongside Agilent OpenLAB software and Agilent CrossLab services, to provide highly efficient workflows for customers.

The new additions to the InfinityLab LC series plus other recently released mass spectrometry instruments will be showcased at HPLC 2017 taking place in Prague, Czech Republic, on 18–22 June.

Agilent InfinityLab LC Purification Solution

Agilent’s new InfinityLab LC purification solution provides a complete portfolio of analytical scale to preparative scale purification systems. Comprised of eleven modules plus accessories and software, the new solution enables laboratories to tailor purification systems to meet their needs. Ranging from highly affordable systems for simple routine purification tasks to fully automated solutions for high-throughput purification labs. Agilent provides a wide range of detectors for fractionation triggering, including mass-spectral detection with the new Agilent LC/MSD or LC/MSD XT systems.

Agilent 1260 Infinity II Prime LC System

A new flagship for more standard HPLC analysis, the 1260 Infinity II Prime LC system delivers outstanding performance on routine analyses and provides an ideal front end to the new Agilent Ultivo Triple Quadrupole Mass Spectrometry system.

The 1260 Infinity II Prime LC provides the highest convenience standard in the 1260 Infinity II LC portfolio plus extended pressure range (up to 800 bar), superior quaternary mixing and specifically designed columns. Automated instrument features reduce the need for manual interaction which increases analytical laboratories’ efficiency. Intelligent System Emulation Technology (ISET), initially only available with 1290 Infinity II LC systems, ensures seamless method transfers from many Agilent and 3rd party legacy instruments.

The improved convenience level of the 1260 Infinity II Prime LC is highlighted with a new local user interface – the Agilent InfinityLab LC Companion.

Agilent 1260 Infinity II Supercritical Fluid Chromatography System

Based on latest technology improvements the new 1260 Infinity II SFC system offers improved performance in supercritical fluid chromatography (SFC). As well as the high separation speed offered by SFC it also enables laboratories to save money and reduce pollution by replacing toxic and flammable solvents often used in normal phase LC.

Agilent enables labs to compare results of SFC and LC runs performed on one system using a hybrid SFC/UHPLC system-configuration of the 1260 Infinity II SFC system or scout for chiral separation conditions using up to 32 columns and 12 solvents in a method development set-up.

“At Agilent, we strongly believe that a one-size-fits-all approach does not respect the performance, functionality and budgetary needs of LC laboratories around the world,” said Dr. Stefan Schuette, vice president and general manager of Agilent’s liquid phase separation division. “That’s why we are introducing a significant range of new Agilent products at the HPLC Conference in Prague, covering the full breadth of our liquid phase separation portfolio – from 1D- to 2D-LC, from reverse phase LC to SFC and from analytical- to preparative-scale purification.”

For more information; www.agilent.com/chem/livepreplc

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A), is a global leader in analytical laboratory technologies. With more than 50 years of insight and innovation, our instruments, software, services, solutions and people provide trusted answers to our customers' most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
19/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch